Nanobiotix Reports Exciting Preclinical Results Using Its nanoXray(TM) Therapeutics Technology to Destroy Tumors
Published: May 18, 2009
PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company, announced today exciting preclinical results using its patented nanoXray therapeutics platform to fight tumors. The preclinical study, performed at Institut Gustave Roussy, one of Europe’s leading cancer treatment centers, showed that an intratumoral injection of NBTXR3 nanoparticles and activated via standard radiation therapy led to complete tumor regression in mice at 60 days, compared to zero tumor regression in mice treated with xray only or NBTXR3 only. The study was led by principal investigator Jean Bourhis, M.D., Ph.D., a prominent radiation oncologist and researcher at Institut Gustave Roussy.